Journal article

Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta

J Martin, DJ Kelly, SA Mifsud, Y Zhang, AJ Cox, F See, H Krum, J Wilkinson-Berka, RE Gibert

CARDIOVASCULAR RESEARCH | OXFORD UNIV PRESS | Published : 2005

Abstract

OBJECTIVE: The pathological accumulation of extracellular matrix is a characteristic feature of diabetic cardiomyopathy that is directly related to a loss of function. Tranilast (n-[3,4-anthranilic acid), used for the treatment of fibrotic skin diseases, has also been shown to inhibit transforming growth factor-beta (TGF-beta)-induced matrix production in kidney epithelial cells. METHODS: To investigate the effects of tranilast in the diabetic heart, we examined its effects in cultured cardiac fibroblasts and then assessed its effects in (mRen-2)27 diabetic rats with established disease (8 weeks after streptozotocin). RESULTS: In vitro studies demonstrated a 58% reduction in TGF-beta1-induce..

View full abstract